This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

United Therapeutics' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Dr. Rothblatt, you may begin your conference.

Martine Rothblatt

Thank you, operator. Good morning to everybody here in North America, and good afternoon or evening to our friends overseas.

I am pleased that we have met our annual revenue target for 2011, which highlights the favorable operating results that we’ve enjoyed this past year.

In addition, we are reaffirming today, our revenue guidance for 2012 and 2013, as revenues from our commercial product lines continue to grow.

I’m pleased to be joined on the call this morning’s conference call by three of our top level executives, Dr. Roger Jeffs who is our President and Chief Operating Officer, and is responsible for clinical development as well as sales and marketing will be joining me this morning and can help field the questions. John Ferrari who is our Chief Financial Officer, and is also responsible for all matters relating to distribution of our product, is also on the call and will be happy to field any questions. And finally, Andy Fisher, who is our Executive Vice President in charge of intellectual property, as well as our Chief Strategy Officer, will also be joining us, and he can help out with any questions relating to IP or strategic matters.

Operator, if you could please open the lines, we can now take the callers’ questions.

Operator, if you could please now open the lines to any questions.

Question-and-Answer Session


(Operator instructions). Our first question today comes from the line Salveen Richter from Collins Stewart. Your line is now open, please go ahead.

Salveen Richter – Collins Stewart

Good morning. Thank you for taking my question. I just wanted to get a sense of what accounted for the negative quarter-over-quarter growth for Remodulin and Tyvaso in 4Q. And then also looking at 2012 guidance, where do you see the majority of the 17% year-over-year revenue growth coming from?

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs